Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 3, Issue 3 , Pages 177-179 , July 2007

Commentary on “Health economics and the value of therapy in Alzheimer’s disease.” Cholinesterase inhibitors in Alzheimer’s disease—Evidence-based or evidence-biased?

References 

  1. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: management of dementia (an evidence-based review) (Report of the Quality Standards Subcommittee of the American Academy of Neurology). Neurology. 2001;56:1154–1166
  2. Caltagirone C, Bianchetti A, Di Luca M, et al. Guidelines for the treatment of Alzheimer’s disease from the Italian Association of Psychogeriatrics. Drugs Aging. 2005;22(Suppl. 1):1–26
  3. Burns A, O’Brien J, Auriacombe S, et al. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol. 2006;20:732–755
  4. Fillit HM, Doody RS, Binaso K, et al. Recommendations for best practices in the treatment of Alzheimer’s disease in managed care. Am J Geriatr Pharmacother. 2006;4(Suppl. A):S9–S28
  5. Lyketsos CG, Colenda CC, Beck C, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry. 2006;14:561–572
  6. Waldemar G, Dubois B, Emre M, et al. Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol. 2007;14:e1–e26
  7. Mayor S. NICE recommends drugs for moderate Alzheimer’s disease. Br Med J [Clin Res]. 2006;332:195
  8. Loveman E, Green C, Kirby J, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and Memantine for Alzheimer’s disease. Health Technol Assess. 2006;10:iii–ivix–xi, 1–160
  9. Green C, Picot J, Loveman E, Takeda A, Kirby J, Clegg A. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer’s disease. Pharmacoeconomics. 2005;23:1271–1282
  10. Cassels A. Questioning the evidence. [letter] Can Med Assoc J. 2006;174:1304
  11. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomised clinical trials. Br Med J [Clin Res]. 2005;331:321–327
  12. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD001190
  13. Birks J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev. 2000;4:CD001191
  14. Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006;1:CD001747
  15. Ritchie CW, Ames D, Clayton T, Lai R. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry. 2004;12:358–369
  16. Takeda A, Loveman E, Clegg A, et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer’s disease. Int J Geriatr Psychiatry. 2006;21:17–28
  17. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289:210–216
  18. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD005593
  19. Lanctôt KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: a meta-analysis. Can Med Assoc J. 2003;169:557–564
  20. Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2004;75:677–685
  21. Perras C, Shakla VJ, Lessard C, Skidmore B, Bergman H, Gauthier S. Cholinesterase inhibitors for Alzheimer’s disease: a systematic review of randomized controlled trials. Technology report no. 58. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2005;
  22. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet. 2004;363:2105–2115
  23. Akintade L, Zaiac M, Ieni JR, McRae T. AD2000: design and conclusions. Lancet. 2004;364:1214
  24. Clarke N. AD2000: design and conclusions. Lancet. 2004;364:1215–1216
  25. Holmes C, Burns A, Passmore P, Forsyth D, Wilkinson D. AD2000: design and conclusions. Lancet. 2004;364:1213–1214
  26. Howe I. AD2000: design and conclusions. Lancet. 2004;364:1214–1217
  27. Black SE, Szalai JP. Are there long-term benefits of donepezil in Alzheimer’s disease?. Can Med Assoc J. 2004;171:1174–1175
  28. Yaari R, Corey-Bloom J. Alzheimer’s disease. Semin Neurol. 2007;27:32–41
  29. Thal LJ, Kantarci K, Reiman EM, et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20:6–15

PII: S1552-5260(07)00485-2

doi: 10.1016/j.jalz.2007.04.389

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 3, Issue 3 , Pages 177-179 , July 2007

Article Tools